BLAINTRAVENOUSPOWDERPriority Review
Approved
Jun 2019
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
21
Data completeness
5/8 — Partial
Priority Review
POLIVY (polatuzumab vedotin) by Roche is vedotin-piiq is a cd79b-directed antibody-drug conjugate with activity against dividing b cells. Approved for not otherwise specified (nos), high-grade b-cell lymphoma (hgbl), greater and 2 more indications. First approved in 2019.
Drug data last refreshed 1h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
POLIVY (polatuzumab vedotin-piiq) is an antibody-drug conjugate (ADC) targeting CD79b on B cells, approved for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma after at least two prior therapies. The drug combines a monoclonal antibody with MMAE, a microtubule-disrupting payload, delivered intracellularly to kill dividing B cells via apoptosis.
$0.001BPart D
PeakProduct is at peak lifecycle stage with modest Part D utilization (76 claims in 2023), suggesting stable but limited commercial momentum typical of specialized oncology therapies.
Mechanism of Action
vedotin-piiq is a CD79b-directed antibody-drug conjugate with activity against dividing B cells. The small molecule, MMAE, is an anti-mitotic agent covalently attached to the antibody via a cleavable linker. The monoclonal antibody binds to CD79b, a B-cell specific surface protein, which is a…
Worked on POLIVY at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.